Clinical Digest: Recent Clinical Trials on Zika Virus
To assist researchers and healthcare practitioners in staying up-to-date with the latest advancements in clinical research, the Clinical Digest Team has compiled a comprehensive list of recent clinical trials related to Zika Virus. These trials are organized by their release dates for your convenience. (Last updated on: 2025-05-02)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that empowers you to read articles, write articles, get answers, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: Recent Clinical Trials on Zika Virus
| Clinical Trial | Contact(s) | Date | |
|---|---|---|---|
| 1 | Phase 3B, Double-blind, Randomized Study to Evaluate The Safety and Non-inferiority of The Humoral Immune Response of The Butantan Dengue Vaccine in Participants Aged 60 to 79 Years Compared to Participants Aged 40 to 59 Years PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a randomized, double-blind (60 -79 years) and open-label (40-59 years), three-arm parallel Phase 3b, multicenter study to evaluate the safety and non-inferiority of the humoral immune response of the Butantan Dengue vaccine (Dengue 1,2,3,4 (attenuated)) in participants aged 60 -79 years (elderly) compared to participants aged 40 to 59 years (adults), with or without previous dengue and healthy based on clinical examination. |
BUTANTAN INSTITUTE | 2025-04-01 |
| 2 | Seroprevalence of Zoonotic and Arboviral Emerging Infections in Exposed Agents from The City of Montpellier: A Transversal Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments). Most of these diseases are found in certain tropical zones, but global warming and increased international trade are modifying their geographical distribution, with a gradual trend towards temperate regions. A number of these pathogens have already been detected in Occitania, including dengue fever, West Nile, leishmaniasis and Q fever. Given the region’s high mosquito population and favorable climatic conditions, other zoonoses have a strong potential to appear in the region, … |
CHARLOTTE BOULLE; | 2025-03-03 |
| 3 | Observational Study of Travellers Pathologies PF:8 Related Papers Related Patents Related Grants Related Experts View Highlight: Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues. The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory. |
FABIEN TAIEB; | 2024-12-09 |
| 4 | A Phase 1 Evaluation of The Protective Efficacy of A Single Dose of The Live Attenuated Tetravalent Dengue Vaccine TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Historical Controls Against Infection With ZIKV-SJRP Challenge PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Zika virus (ZIKV) is an illness people can get from mosquitoes. The infection is generally mild with symptoms that include a fever, rash, red eyes, and joint pain, though most of those infected have no symptoms. Preventing ZIKV is important because if a pregnant person is infected with ZIKV, it can cause birth defects in their unborn child. The goals of this study are to find out if people who have already been infected with one type of ZIKV can get infected with ZIKV a second time, … |
ANNA DURBIN; | 2024-09-24 |
| 5 | A Phase 1 Double-blind, Randomized, Dose Finding Clinical Trial with An Open-label Run-in Part to Assess The Safety and Immunogenicity of An Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase 1 clinical trial consists of an initial open-label sentinel run-in (n=25) and a randomized, double-blind, dose-finding (n=125) investigating three antigen dose levels (low, medium and high) of VLA1601 and bedside mixing of the low-dose formulation with one of the two additional adjuvants (CpG1018®, 3M-052-AF/AP 60-702). VLA1601 will be administered according to a two-dose regimen (i.e., on Day 1 and Day 29). The primary objective of this trial is to assess the safety and tolerability of the vaccine candidate up to 7 days after each vaccination; … |
VALNEVA AUSTRIA | 2024-03-25 |
| 6 | Evaluation of Viral Replication By Tonate Virus (TONV) and Zika Virus (ZIKV), Within An Ex Vivo Trophoblast and Placental Model Related Papers Related Patents Related Grants Related Experts View Highlight: Prospective, non-interventional study carried out after culturing placental trophoblastic tissue ex vivo and infection with Zika and Tonate |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2023-11-01 |
| 7 | A Case-Control Study on The Association Between Periodontal Health and Gingival Crevicular Level of Matrix Metalloproteinase-8 in Post COVID-19 Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this study is; To Assess the association between periodontal health and Matrix metalloproteinase-8 (MMP-8) level in Gingival Crevicular Fluid (GCF) in post COVID-19 patients. |
RANDA NIDAL ALZOUBI; | 2023-08-01 |
| 8 | Hybrid E-zine Health Education Intervention Integrated Within A Mental Health Package for Adolescent Perinatal Depression PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this clinical trial is to develop a hybrid E-zine health education intervention integrated within a mental Health package for adolescent perinatal depression. The main objective is to: – Develop a hybrid Health Educational Intervention offering health promotion and disease prevention services on climate change to perinatal adolescents and their caregivers. – Study the feasibility, acceptability, … |
LOLA KOLA; | 2023-08-01 |
| 9 | Clinical Diagnostic Performance Evaluation of An Anti-Measles IgM Lateral Flow Immunochromatographic Assay for Outbreak Detection and Surveillance in Senegal PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this study is to measure the accuracy of a new measles rapid test when used in clinical health centres in several regions of Senegal. The rapid test will be used to test patients for measles who attend the participating health centres with signs and symptoms suggestive of measles infection. The rapid test can be used with a drop of blood from a finger, … |
CHEIKH TIDIANE DIAGNE; | 2023-07-01 |
| 10 | A Phase 2, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate The Safety and Immunogenicity of The Purified Inactivated Zika Virus Vaccine (PIZV) Administered on Day 1 and 29 and of A Single Booster Dose of PIZV Administered at 6 Months Post Dose 2 in Healthy Subjects Aged 18 to 65 Years in The US PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to describe the side effects and immune response of a candidate vaccine that might protect against Zika. The vaccine called PIZV (purified inactivated Zika virus vaccine) is given by injection in two doses that are 28 days apart in healthy adults. Participants will receive PIZV or placebo and will be followed for 7 days after each dose and up to 6 months after dose 2. In addition, … |
HOWARD SCHWARTZ; | 2023-06-01 |
| 11 | Population Immunity AgaiNst MosquitO-borne Diseases in Vanuatu PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: The Pacific region is facing several emerging and neglected diseases notably mosquito-borne diseases as malaria or arboviroses among which dengue, Ross River, chikungunya and Zika. These diseases are an important cause of illness and death in the Pacific and the occurrence of arboviruses has increased in the recent years. In humans, these mosquito-borne diseases often have very similar clinical presentations (an acute febrile syndrome often self-limiting). However, … |
INSTITUT PASTEUR | 2022-10-17 |
| 12 | A Cluster Randomized, Placebo Control Trial to Evaluate The Efficacy of A Spatial Repellent (Mosquito ShieldTM) Against Aedes-borne Virus Infection Among Children ≥ 4-16 Years of Age in The Gampaha District, Sri Lanka PF:8 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary objective of the study is to demonstrate and quantify the protective efficacy (PE) of a single SR product, in reducing DENV infection and active Aedes-borne virus (ABV) disease in human cohorts. The study design will be a prospective, cluster randomized controlled trial (cRCT). Although not a specific objective of this project, an overall goal is to allow for official recommendations (or not) from the World Health Organization (WHO) for the use of SRs in public health. A WHO global policy recommendation will establish evaluation systems of SR products to regulate efficacy evaluations, thereby increasing quality, … |
KORELEGE HASITHA ARAVINDA TISSERA; | 2022-08-01 |
| 13 | Efficacy and Safety of Topical Methotrexate Gel 1% Coupled With Microneedling in Treatment of Warts : A Prospective Controlled Randomized Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: To study the clinical efficacy of the topically applied MTX hydrogel preparation combined with microneedling to increase drug delivery and efficacy in comparison with cryotherapy in treatment of warts. |
KHULOOD FADHL AHMED ALHAKAMI; | 2022-06-15 |
| 14 | Pathologies Métaboliques Et Infectieuses En Population Générale À La Réunion : Étude REUNION PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of the present study is to determine the prevalence of cardiometabolic and infectious disease in La Reunion (french oversea department and region of France). Known or suspected risk factor for these diseases will also be assessed, such as microbiota, cognitive impairement, social inequalities, and genetics. |
MAXIME COURNOT; | 2022-05-01 |
| 15 | Phase I Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will include 4 cohorts of 14 ZIKV and DENV-naïve female and male subjects, 18 – 40 years of age (total: up to 56 subjects). Within each cohort, 10 subjects will receive ZIKV and 4 subjects will receive a placebo on Study Day 0. Cohorts 1 and 2 (Dose = 10\^2 PFU) will be enrolled first and will enroll only women. Cohorts 3 and 4 (Dose = 10\^2 PFU) will enroll men. |
ANNA DURBIN; | 2022-02-16 |
| 16 | Baromètre Santé Adulte 2021-2022 in People Aged 18 to 64 in New Caledonia Using The WHO STEPwise Approach PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: In 2021-2022, Agence Sanitaire et Sociale Nouvelle Calédonie (ASSNC) is undertaking the Baromètre Santé Adulte for the third time. This study is carried out this year in collaboration with WHO and Institut Pasteur de Nouvelle Calédonie (IPNC). The main objective of this investigation is to describe the current levels of chronic disease risk factors in the adult population of New Caledonia aged from 18 to 64 years old. This study will also help to estimate prevalence of certain diseases (diabetes, hypercholesterolemia, renal failure), seroprevalence of arboviruses (dengue fever, Zika, … |
AGENCE SANITAIRE ET SOCIALE DE NOUVELLE CALÉDONIE | 2021-07-26 |
| 17 | Adherence to Care for Children Born to Mothers With Laboratory Evidence of Confirmed or Possible Congenital Zika Virus Infection During Pregnancy PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Given the magnitude of the epidemic in Puerto Rico, congenital Zika virus infection may have devastating complications to a significant population of children, also affecting families and society at large. This proposal takes a critical first step to ensuring that children with exposure to congenital Zika virus infection receive the follow-up care they need for optimal clinical outcomes. We anticipate that lessons learned from this study may also positively impact models for adherence to early intervention services in Puerto Rico. |
UNIVERSITY OF PUERTO RICO | 2021-07-01 |
| 18 | A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate The Safety, Tolerability, and Immunogenicity of Zika Vaccine MRNA-1893 in Adults Aged 18 Through 65 Years and Living in Endemic and Non-Endemic Flavivirus Areas PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive. |
MODERNATX | 2021-06-08 |
| 19 | Preparing for The Use of A Dengue Vaccine in The French Caribbean Islands of Martinique and Guadeloupe : The DengueSEA Study PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Dengue fever, an arbovirus transmitted by the Aedes mosquito, is a public health problem in all tropical and subtropical regions of the world. There is currently no antiviral treatment and vector control has shown its limits. The 2018 European marketing authorization of the tetravalent chimeric yellow fever / dengue vaccine (Dengvaxia®) is a major step forward in the fight against the disease. Dengvaxia® is indicated for the prevention of dengue due to serotypes DENV 1-4 in subjects aged 9 to 45 years with a history of infection with the dengue virus and living in endemic areas (seroprevalence of at least 70% in the target population). Dengue seroprevalence data in the French Caribbean territories of Martinique and Guadeloupe dates back to 2011 and concerns only adult blood donors aged 18 to 70 years. To date, no data exists for individuals aged 9 to 17 years in the region. In order to implement an optimal vaccine introduction strategy for these territories, the main aim of the DengueSEA study is to estimate the seroprevalence of the Dengue viruses (DENV 1-4) in 9-17 year olds giving a blood sample as part of care in hospital departments of the French Caribbean islands of Martinique and Guadeloupe. |
ANDRE CABIE; | 2021-06-03 |
| 20 | Effectiveness of Quercetin In The Treatment of SARS-COV 2 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name vitamin P because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins. Quercetin is extracted from a variety of plant sources, including the onion peel and the seeds and pods of Dimorphandra mollis, a legume tree native to South America. Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, … |
RIADH BOUKEF; | 2021-06-01 |
| 21 | Disease Registry for Pregnant Women With Suspected COVID-19 or Confirmed SARS-CoV-2 and Their Neonates PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The in-utero exposure of acute viral infection in some instances is proven to have short- and long-term neonatal effects during the postnatal and childhood period and the Zika virus, measles, mumps, and rubella are few examples. COVID-19 is caused by a novel coronavirus strain of unknown consequences. The main purpose of this registry is to collect baseline data and help to establish future studies and hypothesis generation. In addition, … |
SALWA ABO YAQOUB; | 2021-05-25 |
| 22 | The Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ACE2) through scRNA-seq data analyses. The study identified the organs that are at risk and are vulnerable to SARS-CoV-2 infection. Therefore, cells with ACE2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. These results suggest that oral mucosa could be a target of SARS-CoV-2 infection |
ALSHAIMAA AHMED SHABAAN; | 2021-05-20 |
| 23 | Epidemiologic Intelligence Network (EpI-Net) to Promote COVID-19 Testing and Prevention Practices Among Socially Vulnerable Communities in Puerto Rico PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The investigators propose a mixed-methods intervention design to evaluate the acceptability of epidemic intelligence (EpI-Net) intervention using Community Engagement (CE) principles to promote COVID-19 testing and prevention practices in socially vulnerable communities in PR. The team hypothesizes that the integration of lay community leaders, trained in the use of COVID-19 prevention technology tools (EpI-Net), will result in increased COVID-19 testing uptake and prevention practices among the targeted socially and epidemiologically vulnerable communities in Puerto Rico. |
EIDA M CASTRO; | 2021-03-09 |
| 24 | Investigating The Sylvatic Transmission and Reservoir Potential of Zika, Dengue, and Chikungunya Viruses of Co-located Humans and Long-tailed Macaques of Thailand and Cambodia PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Zika, dengue, and chikungunya are spread by mosquitos. These diseases have a major impact on public health. This is especially true in in Southeast Asia. Non-human primates (such as macaques) could play an essential role in spreading these diseases. Researchers want to further understand the relationship between humans and these primates. They want to see how this affects how mosquito-borne viruses are spread in Southeast Asia. Objective: To describe the prevalence of Zika virus, dengue virus, … |
JESSICA E MANNING; | 2021-02-08 |
| 25 | Fase I Clinical Trial on Natural Killer Cells for COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available. This study aims to investigate the safety and efficacy of intravenous infusion of natural killer cells patients with COVID-19. |
LUCIA SILLA; | 2021-01-02 |
| 26 | Quantifying The Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The trial will be conducted in the city of Merida extending ongoing longitudinal cohort to follow a population of 4,600 children 2-15 years old randomly allocated to receive either TIRS treatment or not. If efficacious, TIRS will drive a paradigm shift in Aedes control by: considering Ae. aegypti behavior to rationally guide insecticide applications; the change to preventive control (pre- ABD transmission season rather than in response to symptomatic cases); the use of third generation insecticides to which Ae. Aegypti is susceptible. |
GONZALO VAZQUEZ-PROKOPEC; | 2020-11-03 |
| 27 | Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-Endemic Participants in Cambodia PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Mosquito-borne viruses like dengue cause major illness and death worldwide, particularly in Southeast Asia. When mosquitoes deliver a virus into the skin of humans, they also leave saliva. Researchers want to learn more about skin immunity to mosquito saliva. They hope this will help with future vaccines and treatments for these diseases. Objective: To compare the early and late innate immune response in the skin of Aedes aegypti bitten versus unbitten skin. Eligibility: Healthy people ages 18-45 who live within about 15 km of the study site in Chbar Mon Design: Participants will have 3 visits. The baseline/screening visit will include: Medical and medication history Questions about participants demographic information, mosquito biting risk factors, and responses to mosquito or other insect bites Physical exam Urine sample for some participants Mosquito feeding. A feeding device will be placed on the participant s arm for up to 20 minutes. The insects will feed through a mesh on the bottom of the feeding device. Participants may be given standard treatments for any skin reactions. Blood tests Four skin biopsies taken from bitten and unbitten skin. Local anesthetic will be administered, and a small tool will be used to remove the participant s skin. Participants will have a second visit the next day. They will have a physical exam and blood tests. They will have 1 skin biopsy. Participants will have a final visit about 2 weeks later. They will have a physical exam and blood tests. During the study, participants will be asked to take measures to prevent more mosquito bites. |
JESSICA E MANNING; | 2020-10-27 |
| 28 | A Single Centre, Double-blind, Double-dummy Placebo-controlled, Randomised Phase Ib Study to Evaluate The Safety & Immunogenicity of The Candidate Chikungunya Vaccine ChAdOx1 Chik & The Zika Vaccine ChAdOx1 Zika in Healthy Adults in Mexico PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Phase Ib, single centre, double-blind, double-dummy placebo-controlled, randomised, stepwise dose escalated, vaccine trial to assess the safety and immunogenicity of the candidate ChAdOx1 Chik and ChAdOx1 Zika vaccines, given as a standalone vaccines or in co-administration. Healthy volunteers aged 18-50 years old, residents of the metropolitan area of Monterrey (Mexico), will be recruited as participants |
UNIVERSITY OF OXFORD | 2020-10-23 |
| 29 | A Cluster-Randomized Trial to Evaluate The Efficacy of Wolbachia-Infected Aedes Aegypti Mosquitoes in Reducing The Incidence of Arboviral Infection in Brazil PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: Randomized Trial to Evaluate the Efficacy of Deploying Genetically-engineered Mosquitos to Control Dengue Burden in the City of Sao Jose do Rio Preto, Brazil |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2020-09-09 |
| 30 | Diagnostic Accuracy of COVID-19 Detection Tests in Different Body Fluids of Infected Men and Concordance With Viral Cultures PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: A clinical and experimental study will be carried out in which the clinician will investigate the PCR of the virus early in different body fluids (blood, semen, urine, saliva) and monitor its experimental clearance and evaluate in vitro diagnostic tests and inhibitory factors of viral proliferation. |
RICARDO REGES MAIA DE OLIVEIRA; | 2020-09-01 |
| 31 | Efficacy of Based MRI Contrast Media Against Covid-19 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients (SnPPIX) Mahmoud ELkazzaz(1),Rokia yousry abdelaziz sallam(2) _____________________________________________________________________________________________ _________________________________________________________________________ Abstract : The novel coronavirus pneumonia (COVID-19) is an infectious acute respiratory caused by the novel coronavirus. The virus is a positive-strand RNA virus with high homology to bat coronavirus. Depending on published study in which , conserved domain analysis, homology modeling, and molecular docking were used to compare the biological roles of specific proteins of the novel coronavirus. The principal investigator demonstrated according to previous researches that some viral structural and nonstructural proteins could bind to the porphyrin, … |
MAHMOUD RAMADAN MOHAMED ELKAZZAZ; | 2020-08-01 |
| 32 | Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers: A Randomized-Controlled Trial PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: The rapid spread and high infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) makes identifying an effective prophylaxis agent highly important. One of the important target populations for such intervention who are at high risk of exposure are health care workers (HCWs) who may develop disease and/or expose patients and other HCWs. Hydroxychloroquine (HCQ), currently in usage for treatment of severe Coronavirus Disease 2019 (COVID-19), has in addition to in-vitro activities of inhibition of virus replication and immunomodulation, … |
NESRIN GHANEM-ZOUBI; | 2020-07-01 |
| 33 | Epidemiology and Clinical Characteristics of Emerging and Re-emerging Infectious Diseases PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a prospective observational study to include participants with a spectrum of emerging or unknown pathogens with the objective to determine etiology and clinical characteristics of those diseases. |
SOUNKALO DAO; | 2020-06-18 |
| 34 | Impact of COVID-19 Pandemic in Perinatal Mental Health PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: Introduction: Coronavirus disease 2019 (COVID-19) is a new pathology, declared a public health emergency by the World Health Organization, which can have negative consequences for pregnant women and their newborns. It is estimated that 1 in 5 women will develop a mental illness in the perinatal period. COVID-19 pandemic has been associated with anxiety and depression in the population. The current pandemic is a unique stressor with potentially wide-ranging consequences in the perinatal period, but little is known about the impact of COVID-19 on perinatal mental health. Thus, … |
ANA MESQUITA; | 2020-06-15 |
| 35 | Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the outbreak of coronavirus disease 2019 (COVID-19) are causing public health emergencies. A handful pieces of literature have summarized its clinical and radiologic features, whereas therapies for COVID-19 are rather limited. To evaluate the efficacy of convalescent plasma therapy in COVID-19 patients. |
OSSAMA HAMDY SALMAN; | 2020-05-29 |
| 36 | Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized No Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: In December 2019, patients with pneumonia secondary to a new subtype of Coronavirus (COVID-19) were identified in China. In a few weeks the virus spread and cases started practically all over the world. In February 2020, the WHO declared a pandemic. Severe symptoms have been found in patients mainly with comorbidities and over 50 years of age. At this time there is no proven therapeutic alternative. In vitro studies and observational experiences showed that antimalarial drugs (Chloroquine and hydroxychloroquine) had antiviral activity and increased viral clearance. Ivermectin, on the other hand, … |
CENTENARIO HOSPITAL MIGUEL HIDALGO | 2020-05-04 |
| 37 | Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: The first case of Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were diagnosed in Wuhan, China in 2019. In the first half of 2020 this disease has already converted into a global pandemic. Objectives: To assess the efficacy of Ivermectin in mild cases of COVID-19 patients on the basis of predefined assessment criteria. Study Settings: Fatima Memorial Hospital, Lahore Study Design: Open label randomized control trial. Duration of Study: From 1st May, 2020 to 30th June, 2020.Patients & Methods: Sample size and technique: Sample size was 50 patients; … |
AIJAZ ZEESHAN KHAN CHACHAR; | 2020-05-01 |
| 38 | Neuro-COVID-19: Neurological Complications of COVID-19 Related Papers Related Patents Related Grants Related Experts View Highlight: The prevalence and typical patterns of neurological complications in hospitalized COVID-19 patients admitted to the intensive care units of the University Hospital Zurich will be investigated. The impact of neurological complications among COVID-19 patients on mortality, functional outcome, and organizational outcomes will be analyzed. |
EMANUELA KELLER; | 2020-05-01 |
| 39 | Neurologic Manifestations of COVID 19 in Children PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to perform a secondary analysis of pre-existing de-identified limited datasets obtained from sites participating in Tier 1 (STUDY20040154: Neurologic Manifestations of COVID 19 in Children) and Tier 2 (STUDY20040278: Neuro COVID – Outcomes). The data will be used to determine the prevalence and severity of neurological symptoms among patients requiring critical care admission for confirmed or suspected novel coronavirus (COVID-19) and to determine the predictors for limitation of care in the study population, as well as, … |
ERICKA FINK; | 2020-04-29 |
| 40 | Proactive Care of Ambulatory COVID19 Patients: Open-labeled Randomized Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: On January 9, 2020, a new emerging virus was identified by WHO as being responsible for grouped cases of pneumonia in China. It is a coronavirus, SARS-CoV-2, responsible for the disease COVID-19 (Coronavirus disease). The disease is mild in 85% of cases but the proportion of serious cases requiring hospitalization or intensive care (15%) puts stress on health structures and systems around the world. To limit the influx of patients and avoid overstretching Health systems, … |
JEAN-PHILIPPE LANOIX; | 2020-04-29 |
| 41 | A Clinical Performance Evaluation of The SARS-COV-2 Direct Antigen Rapid Test DART PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The current standard of care for diagnosis of Severe Acute Respiratory Syndrome associated Coronavirus -2 (SARS-CoV-2 ) infection involves sample collection to be prepared and measured via real time-polymerase chain reaction (RT-PCR). This process is often time consuming depending on the level of automation within the laboratory processing the samples. In many cases, sample turn-around times can take hours to several days. A rapid assay that does not require the sophisticated laboratory equipment and techniques could provide a significant advantage to the way practitioners screen and ultimately treat patients. Moreover, … |
KLEPLER N DE ALMEIDA; | 2020-04-24 |
| 42 | Strain Study: To Access The Egyptian COVID-19 Whole Genome (Dominant Strain) By Next Generation Sequencing (NGS) and Compare to The International Worldwide Database PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is an exploratory study that will be performed on confirmed positive COVID-19 samples to identify the dominant viral genome strain in Egyptians using next generation sequencing (NGS). |
HESHAM ELGHAZALY; | 2020-04-20 |
| 43 | A Phase I Study to Determine The Safety and Immunogenicity of The Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a FIH, open-label, dose escalation, phase I clinical trial to assess the safety and immunogenicity of the candidate ChAdOx1 Zika vaccine in healthy volunteers administered intramuscularly. |
ADRIAN V HILL; | 2019-10-21 |
| 44 | Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Zika virus (ZIKV) infection spread throughout the Americas with devastating consequences. Recent limited evidence suggests the potential for neurological effects associated with postnatally acquired ZIKV infection in humans; however, the impact on children is unknown. The researchers will conduct a longitudinal study of approximately 450 Nicaraguan children who were ages 2-12 in 2016 to evaluate the presence and persistence of neurological symptoms associated with ZIKV infection and to test whether ZIKV-infected children are at greater risk for developing neurological outcomes compared to uninfected children. |
JILL F. LEBOV; | 2019-10-01 |
| 45 | Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of A Novel Vaccine Formulation MV-ZIKA-RSP PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is designed to investigate, at first, safety and tolerability of a novel liquid vaccine formulation named MV-ZIKA-RSP, in healthy adults aged 18 to 55 years |
THEMIS BIOSCIENCE | 2019-08-02 |
| 46 | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate The Safety, Tolerability, and Immunogenicity of Zika Vaccine MRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This clinical study will evaluate the safety, tolerability and reactogenicity of mRNA-1893 Zika vaccines in flavivirus seronegative and flavivirus seropositive participants |
MODERNATX | 2019-07-30 |
| 47 | The International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The International Cohort Study of Children Born to Women Infected with Zika Virus (ZIKV) During Pregnancy study is a prospective, observational, international cohort study of children previously enrolled in the ZIP study or other ZIP 2.0 Protocol Team approved ZIKV-cohort study that will continue the longitudinal follow-up of children born with documented confirmed or presumptive in-utero ZIKV exposure (ZIKV-exposed cohort) and children born without documented confirmed or presumptive in-utero ZIKV exposure, … |
WESTAT | 2019-06-12 |
| 48 | Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will explore whether ZIKV is currently responsible for neurological complications, and particularly microcephaly, in Aedes-infested regions of Sub-Saharan Africa (SSA) and Asia. This will inform regional public health strategies, such as vaccination of women of child-bearing age. It will also demonstrate the public health impact of ZIKV infection and increase the understanding of other regional infectious (e.g. cytomegalovirus) causes of microcephaly. |
ARNAUD FONTANET; | 2019-05-20 |
| 49 | Screening For Critical Congenital Anomalies In NICU And Their Out Come in Assiut Universty PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The congenital malformation (CMF) include disturbance in normal process of organogenesis occurring before birth . – The (CMF) are structural ,functional, or (biochemical Molecular) defect presenting at birth. – The structural defect resulting from prenatal insult during period of embryogeneses. – The neonate with congenital malformation have differences in physiology, anatomy, in response to stress. – The (CMF) are important causes of infant disability , illness, deaths. – (CMF) classified into mild, moderate, severe and lethal |
AMIRA THARWAT HELMY; | 2019-03-19 |
| 50 | Pilot Study to Detect DENGUE Virus in Sperm PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to seek the presence of dengue virus in semen, to determine its localization and to assess the efficiency of spermatozoa processing methods to obtain virus free spermatozoa. This is a prospective study involving 15 patients, with acute dengue virus infection and a positive RNA detection in blood or/and urines. These results are important to understand the physiopathology of dengue virus infection and will help to counsel the infected patient in epidemic zona or returning from epidemic country. Moreover, … |
LOUIS BUJAN; | 2019-02-06 |
| 51 | Control of Aedes Breeding Sites With A Dual-action Insecticidal Coating Is Effective in Reducing Dengue Transmission: Cluster-randomised Controlled Trial Study PF:9 Related Papers Related Patents Related Grants Related Experts View Highlight: Effective control of Aedes aegypti mosquitoes in breeding sites with high reproductive rates could have a major impact on reducing arbovirosis in endemic communities. The application of a safe, effective, low cost and sustained insecticide coating (IC) could be an affordable response to dengue for local health services. Therefore, a cluster randomised trial for the application of a new vector control tool (insecticidal coating of water containers) was conducted in the metropolitan area of Cúcuta, Colombia. The IC is an aqueous solution containing polymeric microcapsules of insecticides and insect growth regulators (pyriproxyfen-PPF (0.063%) and alphacypermertrin-ACM (0.07%) in suspension, … |
ROCIO CARDENAS SANCHEZ; | 2019-02-04 |
| 52 | Defining Skin Immunity of A Bite of Key Insect Vectors in Humans PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Mosquitoes and similar insects called sand flies carry parasites that can cause diseases. These viruses and parasites can spread quickly and be difficult to control. How people s bodies respond to insect bites may affect how they get infected. The response to bites is caused by the immune system, … |
MATTHEW J MEMOLI; | 2018-09-05 |
| 53 | Rescuing Neurodevelopment in Zika-Exposed Infants in Grenada PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Implement a randomized controlled trial, evidence-based, culturally adapted, environmental enrichment intervention for the purpose of enhancing neurocognitive outcomes among Zika Exposed Children. |
RANDALL WAECHTER; | 2018-09-03 |
| 54 | Phase I Evaluation of The Safety and Immunogenicity of The Live Attenuated Zika Vaccine RZIKV/D4Δ30-713 in Flavivirus-naïve Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of a single dose of the live attenuated Zika vaccine rZIKV/D4Δ30-713 in adults with no history of previous flavivirus infection. |
ANNA DURBIN; | 2018-07-06 |
| 55 | Investigating Vector-borne Determinants of Aedes-transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Some mosquitos carry viruses that can cause disease. Some examples are dengue and Zika. The mosquitos spread disease by biting people and infecting them with the virus. Children, elderly people, and people who are already sick are especially likely to get infected. Researchers want to learn more to help make new medicines to treat these viral infections. Objective: To learn more about how mosquitos infect people, … |
FABIANO (LUIZ) F OLIVEIRA; | 2018-07-01 |
| 56 | Safety and Pharmacokinetic Evaluation of Zika Virus Immune Globulin in Healthy Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Currently, there are no licensed therapeutics against Zika virus infection. Due to this unmet medical need, Zika Virus Immune Globulin (ZIKV-IG) is being developed as a therapeutic intervention against Zika virus infection. In this first-in-human study, evaluation of ZIKV-IG safety and pharmacokinetics (absorption, metabolism and excretion) will be conducted in healthy adult volunteers. |
VADIM DREYZIN; | 2018-06-27 |
| 57 | World Mosquito Program Noumea – Human Sample Component PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The dengue, Zika and chikungunya arboviruses represent potentially severe infections to which the New Caledonian population is exposed. In the absence of specific treatment or vaccine, vector control remains the method of choice to limit their spread. However, the traditional methods of prevention and vector control measure today face their limits: mosquito resistance to insecticides, difficulty of access and destruction of breeding areas… The World Mosquito Program Noumea project is based on the artificial colonization of the mosquito vector Aedes aegypti by the endosymbiotic bacteria Wolbachia, … |
FRÉDÉRIC TOUZAIN; | 2018-06-25 |
| 58 | Evaluation of The Clinical Performance of The ZIKV Detect™ 2.0 IgM Capture ELISA PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the performance of the ZIKV Detect™ 2.0 IgM Capture ELISA using archived confirmed ZIKV positive and confirmed ZIKV negative human serum samples. |
INBIOS INTERNATIONAL | 2018-04-01 |
| 59 | Longitudinal Clinical and Virological Study Among Symptomatic Patients With Zika Virus Infection in The City of Sao Paulo, Brazil Related Papers Related Patents Related Grants Related Experts View Highlight: Study to enroll up to 1000 adult patients (>18 years) presenting with febrile or rash illness of short duration (<72h) in designated clinics in the State of Sao Paulo, Brazil. |
THOMAS JAENISCH; | 2018-04-01 |
| 60 | Clinical Evaluation of The FilmArray® Global Fever (GF) Panel PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will evaluate the clinical sensitivity and specificity of the FilmArray Global Fever (GF) Panel. |
BIOFIRE DEFENSE | 2018-03-26 |
| 61 | A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess The Safety and Immunogenicity of Two Different Dose Levels of An Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: In this Phase 1 study, two target dose levels of VLA1601, a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide (alum) will be evaluated: 6 antigen units (AU) and 3 AU of inactivated ZIKV vaccine. Each dose will be administered intramuscularly (i.m.) in the deltoid muscle on Days 0 and 28. In addition, an accelerated 2-dose vaccination schedule on Days 0 and 7 will be assessed for both doses. |
VALNEVA AUSTRIA | 2018-02-24 |
| 62 | Effects of Transcranial Direct Current Stimulation on Reward Learning in Subclinical Depression PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This project will test whether transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal cortex (DLPFC) can alter reward learning behaviour in subclinical depression. tDCS is a neuromodulation technique that uses weak electrical current to increase (anodal stimulation) or decrease (cathodal stimulation) the excitability of the stimulated brain region. A growing body of evidence indicates that repeated administration of prefrontal tDCS can ameliorate symptoms of depression. A main characteristic of depression is that patients show a bias towards processing negative relative to positive information. Previously, … |
JACINTA O’SHEA; | 2018-02-02 |
| 63 | Children (CH) Cohort for The Evaluation of Developmental and Neurological Abnormalities in Infants Born to Mothers Residing in Areas With Zika Virus Transmission During Pregnancy PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV) infections in pregnancy and congenital malformations. The study will estimate the absolute and relative risks of congenital malformations and other adverse outcomes of pregnancy among women who become infected with ZIKV during pregnancy compared to uninfected pregnant women, also leading to further validation of the Congenital Zika Syndrome. |
THOMAS JAENISCH; | 2018-01-15 |
| 64 | Structured and Specialized Physical Therapy: Does It Make A Difference for Children With Congenital Zika Syndrome? PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The study aims to evaluate the effects of a specialized physiotherapy protocol aimed at the motor function of children with Congenital Zika Virus Syndrome. First, participants’ anthropometric parameters (weight and length) and motor functions were assessed. After that participant were splited in two groups: Experimental group that uunderwent a one-hour daily protocol (5 times a week) of stimuli and handling based on the neuroevolutionary concept, and motor physical therapy with therapeutic garments (PediaSuit). On the other hand, the control group (CG) kept the therapeutic routine (conventional physical therapy). |
GABRIELA LOPES GAMA; | 2018-01-15 |
| 65 | A Randomized, Double-blind, Placebo-controlled, First-in-Human Phase 1 Study to Evaluate The Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to assess the safety, reactogenicity, and immunogenicity of Ad26.ZIKV.001 at 2 dose levels, 5*10^10 viral particles (vp) and 1*10^11 vp, administered intramuscularly as single dose and as 2-dose schedules in healthy adults. |
JANSSEN VACCINES & PREVENTION B V | 2017-11-26 |
| 66 | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to describe the safety, tolerability and immunogenicity of two doses of purified inactivated Zika virus vaccine (PIZV) given 28 days apart. Three different vaccine doses containing different protein concentrations (2, 5 or 10 microgram [mcg]) each, will be given as 2 dose schedule to flavivirus naive and primed healthy adults. Participants will be followed for 7 days post each dose for tolerability and up to 6 months post dose 2 for safety. Immunogenicity assessment will be performed at 28 days post each dose and 6 months post dose 2. In addition, … |
TAKEDA | 2017-11-13 |
| 67 | Applying Wolbachia to Eliminate Dengue (AWED): A Non-blinded Cluster Randomised Controlled Trial to Assess The Efficacy of Wolbachia-infected Mosquito Deployments to Reduce Dengue Incidence in Yogyakarta, Indonesia PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: This cluster randomised trial will evaluate the efficacy of Wolbachia-infected Aedes aegytpi mosquitoes in reducing dengue cases in Yogyakarta City, Indonesia |
RIRIS ANDONO AHMAD; | 2017-11-08 |
| 68 | World Mosquito Program – Colombia (WMP-COLOMBIA): The Impact of City-wide Deployment of Wolbachia-infected Mosquitoes on Arboviral Disease Incidence in Medellin and Bello, Colombia PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Study setting: Medellin and Bello municipalities, Colombia Health condition(s) studied: Dengue, Zika and chikungunya virus infection Intervention: Deployment of Wolbachia-infected Aedes aegypti mosquitoes in Medellin and Bello. Study design: 1. An interrupted time-series analysis utilising routine disease surveillance data collected by the Medellín and Bello Health Secretariats, which aims to compare incidence of dengue, chikungunya and Zika pre- and post-Wolbachia release. 2. A test-negative study using an incident case-control design, which aims to quantify the reduction in disease incidence among people living within a Wolbachia-treated zone compared with an untreated zone that has a similar dengue risk profile at baseline. |
UNIVERSIDAD DE ANTIOQUIA | 2017-10-25 |
| 69 | Prospective Cohort Study of HIV and Zika in Infants and Pregnancy PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to compare the incidence of Zika virus (ZIKV) infection among pregnant women with and without Human Immunodeficiency Virus (HIV) infection and to determine the risk of adverse maternal and child outcomes associated with ZIKV/HIV co-infection across clinical sites in the continental United States (U.S.), Puerto Rico (P.R.) and Brazil. |
WESTAT | 2017-08-23 |
| 70 | Study on The Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The Zika infection is a viral disease that is transmitted to humans by the same mosquito that transmits Dengue and Chikungunya fever. The Zika virus has been found in various body fluids such as urine, blood and semen, but we do not know how long it persists in these fluids. For example, parts of the virus were reported to persist in semen after six months of the onset of symptoms, but we do not know if the virus can stay longer. In this way, … |
GUILHERME AMARAL CALVET; | 2017-07-21 |
| 71 | Survey of Symptoms and Dermatologic Characterization Associated With Zika Virus Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to determine whether any diagnostic patterns exist in the symptom presentation of Zika Virus. |
ROOPAL KUNDU; | 2017-07-06 |
| 72 | Sero-epidemiology of Priority Arboviruses in French Guiana PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: Dengue is an important public health problem despite the efforts of local health authorities to mitigate the impact of epidemics and the epidemiology of dengue evolved from an endemo-epidemic to a hyper-endemic state. In late 2013, the first local transmission of chikungunya virus in the Americas was identified in Caribbean countries and territories including French Guiana. Rapidly, more than 16,000 suspected local Health authorities had reported cases. In May 2015, … |
CLAUDE FLAMAND; | 2017-06-09 |
| 73 | Phase 1, Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial to Evaluate 2 Doses of 3 Sequentially Escalating Cohort of BBV121 in Healthy Adult Dengue Sero-Negative and Dengue Sero-Positive Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: To evaluate the safety, tolerability, and immunogenicity of two-doses of three-sequentially escalating cohort (2.5 µg, 5 µg and 10 µg) of BBV121 (purified inactivated adsorbed Zika virus vaccine) compared with Placebo (Alum). The investigational product is administered intramuscularly on Day 0 and 28 with safety and immunogenicity testing on Day 0, 28 and 56, and Month 6, 9 and 12 |
BHARAT BIOTECH INTERNATIONAL | 2017-06-03 |
| 74 | Efficacy of Aquatic Physiotherapy in Stress Level and Muscle Tone of Children Between 3 and 24 Months With Microcephaly By Zika Virus Congenital Syndrome PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Microcephaly associated with Congenital Syndrome of the Zika virus (SCVZ) was highlighted due to atypical structural and behavioral changes of the central nervous system. Such changes contribute to the appearance of functional impairments and difficulties of adaptation of the child to the necessary therapeutic follow-up. In this context, the search for adjuvant therapies that allow better management of these alterations has grown and, given its advantages, aquatic physiotherapy may be an auxiliary resource in the care of this population. The aquatic environment is capable of promoting a state of relaxation that, when associated with a kinesiotherapy protocol, … |
MILENA GUIMARÃES MONTEIRO; | 2017-06-01 |
| 75 | Pregnant Women (PW) Cohort for Evaluation of Risks of Congenital Malformations and Other Adverse Pregnancy Outcomes After Zika Virus Infection (Part of ZIKAlliance) PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV) infections in pregnancy and congenital malformations. We will estimate the absolute and relative risks of congenital malformations and other adverse outcomes of pregnancy among women who become infected with ZIKV during pregnancy compared to uninfected pregnant women, also leading to further validation of the Congenital Zika Syndrome. |
THOMAS JAENISCH; | 2017-05-24 |
| 76 | Randomized, Double-Blind, Controlled, Parallel Group Study With The INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Stage A: To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in patients who require RBC transfusion support. Stage B: To provide early access to the INTERCEPT pathogen reduction system for RBC in regions where a substantial proportion of the population has been infected or is at risk of a transfusion-transmissible infection. The objectives and design of Stage B will be reassessed on the completion of Stage A, in consultation with the FDA. |
CERUS | 2017-05-11 |
| 77 | Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate The Optimal Dose of MV-ZIKA, A New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Double blinded, randomized, placebo-controlled, dose finding, multi-center, phase 1 trial in 48 healthy volunteer subjects. After completion of screening procedures, the subjects are randomized to one of four treatment groups (different dosage strengths and placebo) All subjects will receive study treatment at day 0 and will return on day 28. Subjects randomized to treatment groups with two vaccinations will receive a second treatment at day 28. Subjects will return on day 56 for the final visit. |
THEMIS BIOSCIENCE | 2017-05-03 |
| 78 | Prospective Surveillance and Case Definition Study of Zika Virus Disease and Infection in Adolescents and Adults in Latin America in Preparation for An Efficacy Trial of A Zika Virus Whole Virion, Purified Inactivated Vaccine PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: This prospective, surveillance study will assess the operational Zika virus definition for use in future Zika purified inactivated virus (ZIKV) vaccine efficacy trials in order to identify Zika virus disease (ZVD) cases among the study cohort. |
SANOFI PASTEUR A SANOFI COMPANY | 2017-04-29 |
| 79 | VRC 705: A Phase 2/2B, Randomized Trial to Evaluate The Safety, Immunogenicity and Efficacy of A Zika Virus DNA Vaccine in Healthy Adults and Adolescents PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: This was a multicenter, randomized study to evaluate the safety, immunogenicity, and efficacy of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo. In Part A, the primary objective was to evaluate the safety and tolerability of the vaccine in different vaccination regimens. In Part B, the primary objectives were to evaluate the safety and efficacy of the vaccine compared to placebo. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2017-03-29 |
| 80 | Estimated Cumulative Incidence of Zika Infection at The End of The First Epidemic in The French West Indies in A Sample of Patients Followed for HIV Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will estimate the cumulative incidence of Zika infection at the end of the first epidemic in the French West Indies in a sample of patients followed for HIV infection. |
ANDRE CABIE; | 2017-03-21 |
| 81 | A Pilot Study Examining for The Presence of Fecal Coliforms in Peruvian Water Sources and The Association of Tropical Diseases Within Peru PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Tropical diseases are continuously on the rise throughout the world as they are spreading and manifesting in various locations globally. The more prominent vector tends to be the mosquito after it bites a previously infected host. The viruses of Zika, Chikungunya, and Dengue are some of the tropical diseases that are affecting large populations and expanding rapidly. Developing countries are at the highest risk because of the lack of preventive methods that are customarily demonstrated in developed countries. Sanitation issues complicate the problem as contaminated wastewater is ideal for mosquitos to lay eggs. In addition, … |
TRENTICE LAZARD; | 2017-03-17 |
| 82 | Using Systems Vaccinology to Elucidate The Effects of Anti-inflammatory Therapy on Immune Response After Vaccination With A Live Attenuated Vaccine PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Since the 1st pandemic of the 21st century caused by SARS coronavirus, the world has experienced outbreaks of swine origin H1N1 influenza, Ebola and Zika viruses, which have all resulted in global health crises. Rapid mass vaccination with an effective vaccine such as a live attenuated vaccine, of vulnerable immune-naïve populations to establish herd immunity is an approach to control outbreaks. Such live attenuated vaccine had been used with great success in sporadic yellow fever outbreaks and recently successfully employed in Ebola field trial, both of these diseases have the potential for pandemic spread. Indeed, … |
JENNY DR LOW; | 2017-03-08 |
| 83 | Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate The Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered By The Intramuscular Route in Adult Subjects Who Reside in A Flavivirus Endemic Area PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is randomized, double-blinded, placebo-controlled, Phase 1, dose de-escalation study to evaluate the safety, reactogenicity, and immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) administered to healthy male and non-pregnant female adult subjects. This study will enroll 90 healthy male and non-pregnant female subjects between the ages of 21 and 49 and will be conducted at Ponce Medical School Foundation, Inc.-CAIMED in Ponce, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2017-02-24 |
| 84 | Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate The Safety and Immunogenicity of AGS-v, A Universal Mosquito-Borne Disease Vaccine PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Mosquitos carry diseases that cause major health problems and death worldwide. The AGS-v vaccine targets proteins in mosquito saliva. This may help prevent many mosquito-borne diseases. It might also reduce the lifespan of the mosquito that bites the vaccinated person. Objective: To see if the AGS-v vaccine is safe in humans and how it affects the immune system. Eligibility: Healthy adults ages 18-50 Design: Participants will be screened another study. Participants will be randomly assigned to get either the vaccine with a booster vaccine, the vaccine without the booster, … |
MATTHEW J MEMOLI; | 2017-02-15 |
| 85 | A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate The Safety and Immunogenicity of MRNA 1325 Zika Vaccine in Healthy Adults in A Non-endemic Zika Region PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The clinical study will assess the safety, tolerability, and immunogenicity of mRNA-1325 in healthy adult subjects. |
MODERNATX | 2016-12-21 |
| 86 | VRC 320: A Phase I, Randomized Clinical Trial to Evaluate The Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: People get Zika virus from infected mosquitos. They usually don t get very sick. But birth defects were reported in babies born to mothers who had Zika infection. In rare cases, … |
GRACE L CHEN; | 2016-12-12 |
| 87 | A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate The Safety and Immunogenicity of An Accelerated Vaccination Schedule With A Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a phase 1 trial of one or more administrations of Zika Virus Purified Inactivated Vaccine (ZPIV). The trial will be conducted under a placebo controlled, double-blind, randomized allocation of study product. There are four groups in the study. Each group is testing a different vaccine schedule. |
KATHRYN STEPHENSON; | 2016-12-08 |
| 88 | A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate The Safety, Reactogenicity, and Immunogenicity of An Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Phase 1 study to evaluate two doses of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) administered 28 days apart. The study will enroll 75 flavivirus naïve healthy adult subjects into 3 equal groups sequentially. Each group will include 20 ZPIV recipients and 5 placebo recipients. Group 1 will receive two ZPIV or placebo doses 28 days apart. Those in Group 1 who consent to a third ZPIV dose will receive 5.0 mcg dose of ZPIV or placebo administered IM on Day 224. Group 2 subjects will receive a two-dose regimen of IXIARO® 28 days apart; … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2016-11-01 |
| 89 | Phase 1, Double-blinded, Placebo-Controlled Study of The Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered By The Intramuscular Route in Flavivirus Naïve Adult Subjects PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is a study to evaluate the safety of ZPIV. Three dose levels may be evaluated. The entire duration of each subject’s participation is approximately 14 months including recruitment and collection of data on the safety and reactogenicity of the study vaccine and samples for the assessment of immunogenicity. This study is expected to take approximately 30 months to complete from initiation through availability of a final report on the primary outcomes of safety and the secondary outcomes of humoral immunity to ZIKV. The Primary objectives of this study are to 1. Assess the safety and reactogenicity of a homologous prime boost regimen of ZPIV given at three different dose levels and 2. Compare the safety and reactogenicity profile of ZPIV after each vaccination and between dosage groups. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2016-10-14 |
| 90 | Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection During The First or Second Trimester of Gestation PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Introduction: It is estimated that more than one million Brazilians were infected by zika virus in the last two years. Brazilian researchers first noted the virus’s potential association with microcephaly. Objective: This study aimed to describe the motor performance of children aged between 6-18 months with the diagnoses of congenital Zika syndrome. Method: This is a cross-sectional, prospective and descriptive study. The study population consisted of 31 children. Participants were evaluated using Alberta Infant Motor Scale (AIMS) and Gross Motor Function Measure (GMFM). |
CARLOS BANDEIRA DE MELLO MONTEIRO; | 2016-08-02 |
| 91 | VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate The Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: The Zika virus is passed to humans by infected mosquitos. It usually causes fever, rash, joint pain, and red eyes. Recently, some cases of microcephaly (abnormally small head) were reported in babies born to mothers infected with the Zika virus. Rare cases of a severe nerve weakness called Guillain-Barr(SqrRoot)(Copyright) syndrome were reported in some people with Zika virus infection. There is currently no cure for or vaccine against the infection. VRC-ZKADNA085-00-VP is a new vaccine that instructs the body to make a small amount of Zika virus protein. The body may use this to build an immune response. Objective: To see if VRC-ZKADNA085-00-VP is safe and causes any side effects. Eligibility: Healthy people ages 18 35 Design: Participants will be screened through a separate protocol with: – Medical history – Physical exam – Lab and urine tests Participants will be randomly assigned to 1 of 4 study groups. They will have about 18 clinic visits over 2 years. Most will occur in the first year, with long-term follow-up visits at months 18 and 24. Visits include a physical exam and blood and urine tests. Participants will have vaccine injections. A high-pressure device pushes the vaccine through the skin and into the muscle of the upper arm. They will have 2-3 injections depending on their group. Vaccine visits last 4-6 hours. Others last 1-2 hours. Participants will keep a diary for 7 days after each injection. They will record their temperature and measure any skin changes at the injection site each day. Participants might have extra visits and blood tests if they have health changes. |
MARTIN R GAUDINSKI; | 2016-08-02 |
| 92 | Phase I, Placebo-Controlled, Double-Blind Study To Evaluate The Safety, Tolerability, AND Immunogenicity Of GLS-5700, Administered ID Followed By Electroporation In Dengue Virus-Seropositive Adults PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus. This is a Phase 1 clinical trial of this vaccine which encodes for the premembrane-membrane and envelope regions of Zika virus. Zika virus, first discovered in the Zika forest in 1947, has caused a large epidemic in South America, Central America, … |
GENEONE LIFE SCIENCE | 2016-08-01 |
| 93 | Phase I, Open-label, Dose-Ranging Study to Evaluate The Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed By EP in Dengue Virus-Naïve Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus. ZIKA-001 is the first in man clinical trial of this vaccine which encodes for the premembrane-membrane and envelope regions of Zika virus. Zika virus, first discovered in the Zika forest in 1947, has caused a large epidemic in South America, Central America, … |
GENEONE LIFE SCIENCE | 2016-07-01 |
| 94 | Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: In this prospective observational study the investigators will report on 20 male subjects with proven WHO-classification Zika infection. These subjects will be followed up for a maximum of 12 months to observe the presence, viral load and infectivity of Zika virus (ZIKV) in semen over time. |
CATHERINE MINTO-BAIN; | 2016-07-01 |
| 95 | The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01) PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will evaluate subjects with fever and/or rash to determine the percentage of those infected by the Zika, Chikungunya, or Dengue virus. The study will also compare the clinical signs, symptoms, and lab abnormalities related to each virus, to better specify each virus’s characteristics. |
PABLO FRANCISCO BELAUNZARÁN ZAMUDIO; | 2016-06-21 |
| 96 | Study of Zika Virus and Related Arbovirus Infections in Deferred Blood Donors PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Zika virus is mostly passed on by the bite of an infected mosquito. It usually causes mild illness. But in pregnant women it can cause serious birth defects to the baby. The virus can also spread by blood transfusion and sexual intercourse. This is why the U.S. Food & Drug Administration (FDA) recommended that people should not give blood if possibly exposed to Zika virus. Dengue virus and chikungunya virus are passed by the same mosquitoes as Zika virus. These can cause severe reactions if passed through transfused blood. Donated blood is usually not tested for these three viruses. Researchers want to count the infections in people who have been exposed because of travel or sexual exposure. They want to learn the risk these viruses might pose to the U.S. blood supply. They also want to study the natural history of these viruses by following infected people over time. Objective: To study the risk of Zika, dengue, and chikungunya viruses to the U.S. blood supply. Eligibility: Adults age 18 or older who were turned down for donating blood because of possible exposure to certain viruses. Design: Participants will have blood and urine tests. They will answer questions about their travel. They will be called in about a week with virus test results. Participants with negative results do not have any more study visits. Participants with positive results will be asked to stay in the study for 6 months. They will have weekly clinic visits and tests until results are negative for 2 straight weeks. Once test results are negative, they will have monthly visits. Visits will include physical exams, blood and urine samples, and optional semen samples from men. Most people will have 3-4 weekly visits and 5 monthly visits. |
ROBERT D ALLISON; | 2016-06-08 |
| 97 | TRMC-Bio Molecular Profiling of Gut Microbiome, Microbiome Metabolome, Serum Chemistry, and Metabolism-Associated SNPs in Elite Athletes PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This research is being done to investigate fecal microbiome and metabolome as well as serum analytes and single nucleotide polymorphisms in Olympic athletes in comparison with other elite athletes. |
BRENT A. BAUER; | 2016-06-03 |
| 98 | International Prospective Observational Cohort Study of Zika in Infants PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: The overall objective of this multisite, multicountry Zika in Infants and Pregnancy (ZIP) study is to assess the strength of the association between Zika virus infection (ZIKV) during pregnancy and adverse maternal/fetal outcomes and the risk of vertical transmission. The study will prospectively enroll a cohort of pregnant women up to 17 weeks and 6 days gestation and subjects at any gestational age with acute Zika infection, confirmed by serology or PCR (polymerase chain reaction) test. The study will follow these women through their pregnancy to identify for clinical evidence of acute ZIKV, … |
RICARDO XIMENES; | 2016-06-01 |
| 99 | Études Observationnelles Des Conséquences Néonatales Et Pédiatriques De L’Infection À Virus Zika Au Cours De La Grossesse Pendant L’épidémie Des Départements Français D’Amérique De L’année 2016 PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The Zika epidemic has spread into the three French Overseas Departments in the Caribbean (DFAs). It is therefore urgent to set up tools to collect clinical and paraclinical data for the evaluation of potential complications due to having ZIKV infection during pregnancy. This study is meant to collect, within usual care practices, … |
OLIVIER FLECHELLES; | 2016-06-01 |
| 100 | Pilot Study to Detect Zika Virus in Sperm PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to seek the presence of ZIKV in semen, to determine its localization and to assess the efficiency of spermatozoa processing methods to obtain virus free spermatozoa. |
LOUIS BUJAN; | 2016-05-06 |
| 101 | Risk Evaluation of Fetal Nervous System and Neurodevelopment Disorders in Infants of Women Exposed to Zika Virus Infection During Pregnancy PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This prospective cohort study will determine the natural history of fetal exposure to Zika virus (ZIKV) and its effects on the fetus and newborn with emphasis on neurodevelopment outcome. Exposure of the fetus will be determined by maternal symptomatology, RT-PCR ZIKV (blood and urine) and serologic test specific for ZIKV. Neonates will be classified according to trimester of infection and as exposed and unexposed to ZIKV. |
MARIO AUGUSTO ROJAS; | 2016-05-01 |
| 102 | Études Observationnelles Des Conséquences De L’Infection À Virus Zika Au Cours De La Grossesse Pendant L’épidémie Des Départements Français D’Amérique De L’année 2016 PF:9 Related Papers Related Patents Related Grants Related Experts View Highlight: The Zika (ZIKV) epidemic has spread into the three French Overseas Departments in the Caribbean (DFAs). It is therefore urgent to set up tools to collect clinical and paraclinical data for the evaluation of potential complications due to having ZIKV infection during pregnancy. This study is meant to collect, within usual care practices, clinical and paraclinical information which will allow the precise description of the consequences of ZIKV infection occurring during pregnancy. |
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE FRANCE | 2016-04-01 |
| 103 | Persistence of Zika Virus in Semen After Acute Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a prospective observational laboratory evaluation of the persistence rate of zika virus (ZIKV) infection in semen by real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), and assessment of ZIKV replication-competence in semen by isolation of ZIKV. Evaluation of the persistence of ZIKV and its replication-competence in semen samples will increase the understanding of the risk of sexual transmission of ZIKV infection in the post-viremic phase in non-epidemic settings. |
INSTITUTE OF TROPICAL MEDICINE BELGIUM | 2016-02-01 |
| 104 | Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The recent increase in the number of cases of congenital microcephaly observed in Brazil is a reason of great concern. This increase occurred a few months after Zika virus (ZIKV) was introduced in the country, which was associated with reports of pregnant women presenting fever and rash illness during pregnancy. Thus, the hypothesis of a relationship between ZIKV infection and microcephaly became plausible. However, studies on the pathophysiology of maternal ZIKV infection, its consequences for the fetus, … |
MARIA E MOREIRA; | 2016-01-02 |
| 105 | Neurovirus Emerging in The Americas Study (NEAS): Neurologic Manifestations of The Arbovirus Dengue, Chikungunya and Zika Infections in Colombia PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a multi-center case-control study that aims to define the association between the exposure to an arbovirus infection and the development of a neurological syndrome in patients from Colombia. The study makes part of the Neurovirus Emerging in the Americas Study (NEAS) that is a collaborative effort that looks to combine the efforts of researchers, healthcare providers and patients in Colombia to establish a comprehensive registry of the clinical, radiological and laboratory profile of patients with new onset of neurological diseases associated mosquito-borne viruses, known as arboviruses. |
CARLOS A PARDO-VILLAMIZAR; | 2016-01-01 |
| 106 | Spatial Repellent Products for Control of Vector-borne Diseases – Dengue PF:8 Related Papers Related Patents Related Grants Related Experts View Highlight: Dengue viruses are the most medically important arthropod-borne pathogens worldwide, with transmission occurring in most tropical and sub-tropical regions. An estimated 390 million infections occur yearly. Although, there are considerable ongoing efforts to develop a vaccine, … |
UNIVERSITY OF NOTRE DAME | 2015-06-01 |
| 107 | An Open Label Study of IgG Fc Glycan Composition in Human Immunity PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: In order to produce better more effective vaccines, it is important to understand the particulars of why individuals have an effective or ineffective immune response to vaccination. We are going to examine specific aspects of the antibody (IgG Fc glycan) made by healthy volunteers who receive different vaccines or who have a viral infection to understand the nature of an effective (or less effective) vaccine response. The results of this research could be used to develop adjuvants to increase/ improve vaccine response. |
TAIA T WANG; | 2013-03-01 |
| 108 | Descriptive and Prognostic Study of Arbovirus Infections in France, Based on A Hospital Cohort of Children and Adults With Suspected Arbovirose PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: There are hundred of arbovirus which have been shown to cause disease in humans. Their most common clinical symptoms are algo-eruptive (dengue, chikungunya, zika), hemorrhagic fever (dengue, yellow fever, Crimean-Congo hemorrhagic fever), neurological (West Nile, Zika, dengue, Japanese encephalitis) or arthritic afflictions (Chikungunya, O’nyong nyong). Dengue is a mosquito-born viral disease caused by 4 different serotypes of virus. Dengue fever (DF) is defined by the sudden onset of fever with non-specific constitutional symptoms, … |
ANDRE CABIE; | 2010-06-01 |